MetabolicOncology
Overcoming immunotherapy resistance in solid tumors.
THE PROBLEM
Checkpoint inhibitors transformed cancer treatment.
For most patients, they do not work.
80%
of patients with solid tumors fail to respond to checkpoint inhibitors.
The founding thesis: metabolic dysfunction in cancer patients blocks immunotherapy from working.
THE EVIDENCE
Independent published studies involving hundreds of thousands of patients report 40 to 60 percent lower cancer mortality with correction of metabolic dysfunction before immunotherapy.
No company has built a prospective clinical program around this published evidence.
THE OPPORTUNITY
6–8million
New cancer cases per year in the platform’s global target population.
TPM targets metabolic dysfunction that limits response to immune checkpoint inhibitors.
13 cancer indications.
CLINICAL DEVELOPMENT
TPM has partnered with one of the world’s largest insurers to insure clinical trial failure risk per indication.
THE PLATFORM
A designed molecule.
A validated diagnostic.
728 patent claims.
Novel Therapeutics
A proprietary molecule designed to prepare the immune system for checkpoint inhibitor therapy.
Companion Diagnostic
A validated diagnostic that assesses the likelihood of response before checkpoint inhibitor treatment.
Broad IP Protection
The patent portfolio spans the protocol, molecule, delivery platform, diagnostic, and 13 cancer indications.
CONTACT
Scientific collaboration,
partnerships, and
investment inquiries.